Home › NDC Lookup › Ingredients › Multivitamin › 59088-0022-54
⚪image loading
(from DailyMed)

Boostervite Multivitamin 18 mg; 50 mg; 2.5 mg; 300 ug; 10 mg; 10 mg; 100 mg; 1000 ug; 100 ug; 10 mg Tablet, 30-count — NDC 59088-022-54 (Billing 59088-0022-54)

by PureTek Corporation · 30 TABLET in 1 BOTTLE, PLASTIC

This is a package of 30 tablets of Boostervite Multivitamin 18 mg; 50 mg; 2.5 mg; 300 ug; 10 mg; 10 mg; 100 mg; 1000 ug; 100 ug; 10 mg Tablet from PureTek Corporation, marketed since Jun 2026 and currently FDA-listed. It is this product's only package size.

NDC 59088-0022-54
🏷️ FDA NDC (as labeled) 59088-022-54 billing pads the product segment with a zero
Rx only On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Oct 1, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 59088-022-54 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
59088 labeler · 022 product · 54 package
Package marketed since
Jun 19, 2026
Sample package
No — commercial package
Listing certified through
Dec 31, 2027
Billing quantity
30 EA per package
Barcode (UPC)
0359088022542
FDA record last changed
Oct 1, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 59088-022-54
Product NDC 59088-022
11-digit billing NDC 59088002254
NCPDP billing unit EA — each (per item)
UNII R5L488RY0Q, 19F5HK2737, 5A9KE2L9L3, 6SO6U10H04, TLM2976OFR, 25X51I8RD4 +10 more
UPC 0359088022542
SPL Set ID 53efbf65-8844-8486-e063-6394a90a51d3
Established class (EPC) Vitamin C; Vitamin D
Chemical class Ascorbic Acid; Vitamin D
DEA schedule Non-controlled
Marketing category UNAPPROVED DRUG OTHER
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2026-06-19
Route ORAL
Dosage form TABLET
Substance FERROUS FUMARATE; PANTOTHENIC ACID; ORANGE JUICE; BIOTIN; RIBOFLAVIN; NIACINAMIDE; ASCORBIC ACID; LEVOMEFOLATE CALCIUM; METHYLCOBALAMIN; THIAMINE MONONITRATE; PYRIDOXINE HYDROCHLORIDE; CHOLECALCIFEROL; BROCCOLI SPROUT; PRUNUS CERASUS (BITTER CHERRY) FRUIT
Why two NDCs? The FDA registers this code as 59088-022-54 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 59088-0022-54. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

🧪 What is this product?

Boostervite Multivitamin is an oral tablet containing a blend of vitamins, minerals, and plant extracts. The product includes vitamin C (ascorbic acid), B vitamins (thiamine, riboflavin, niacinamide, pantothenic acid, pyridoxine, biotin, and methylcobalamin), vitamin D (cholecalciferol), folate (levomefolate calcium), iron (ferrous fumarate), and various plant-based ingredients like broccoli sprout, kale, bitter cherry fruit extract, and orange juice. These vitamins and minerals are typically found in dietary supplements and are commonly used to support general nutritional intake. This product is marketed without an FDA-approved application.

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eachPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
ℹ️
No price is published for this exact package yet. CMS surveys NADAC per package size, so a different pack of the same drug often has one.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
59088-0022-54 You're viewing this Main listing 30 TABLET in 1 BOTTLE, PLASTIC 2026-06-19 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Boostervite 18 mg/1; 50 mg/1; 2.5 mg/1; 300 ug/1; 10 mg/1; 10 mg/1; 100 mg/1; 1000 ug/1; 100 ug/1; 10 mgthis 59088-0022-54 PureTek 30 tablets — — FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2026
On the market since
Jun 2026
📍
2026
Currently FDA-listed
listed with the FDA
🔒
·
No generic listed yet
brand only
ℹ️No FDA-approved generic found

We did not find an FDA-approved generic match for this exact strength, form and route.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerPureTek Corporation
Labeler code59088
First marketedJun 2026
Product typeHuman Prescription Drug
Portfolio178 products on file

More NDCs from PureTek Corporation labeler code 59088

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications ⚠️ Warnings 🤒 Adverse Reactions 🔄 Drug Interactions 👥 Use in Specific Populations 🆘 Overdosage 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📦 Storage and Handling 📋 Description ⚠️ Precautions 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 34 words ▾

INDICATIONS AND USAGE: Boostervite™ contains a combination of vitamins, minerals, and botanical extracts intended to supplement nutritional intake in patients with low energy associated with nutritional needs, under the supervision of a healthcare provider.

⏱️ Dosage and Administration 35 words ▾

DOSAGE AND ADMINISTRATION: Take one (1) tablet daily with food, or as directed by a healthcare provider. Dosage may be adjusted based on individual patient requirements and clinical response. Do not exceed the recommended dose.

⛔ Contraindications 29 words ▾

CONTRAINDICATIONS: This product is contraindicated in patients with known hypersensitivity to any of its ingredients; also, all iron compounds are contraindicated in patients with hemosiderosis, hemochromatosis, or hemolytic anemias.

⚠️ Warnings 58 words ▾

WARNING: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. Keep this product out of reach of children. In case of accidental overdose, call a doctor or poison control center immediately. Administration of folate alone is improper therapy for pernicious anemia and other megaloblastic anemias in which vitamin B12 is deficient.

🤒 Adverse Reactions 141 words ▾

Adverse Reactions: Allergic sensitization and other hypersensitivity reactions have been reported with oral folate supplementation. Ferrous Fumarate: Gastrointestinal disturbances, including anorexia, nausea, diarrhea, and constipation, have been reported. These effects are generally mild and may resolve with continued use.

Administration of Boostervite™ with food may reduce the occurrence of gastrointestinal disturbances, although iron absorption may be decreased when taken with meals. Adverse reactions have been reported with specific vitamins and minerals but generally at levels substantially higher than those contained herein. However, allergic and idiosyncratic reactions are possible at lower levels.

Iron, even at the usual recommended levels, has been associated with gastrointestinal intolerance in some patients. Call your healthcare provider for medical advice about side effects. You may report side effects to PureTek Corporation at 1-877-921-7873 .

You may also report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.

🔄 Drug Interactions 42 words ▾

Drug Interactions: Boostervite™ is not recommended for use in patients receiving levodopa, as pyridoxine may antagonize the effects of levodopa. Pyridoxine may antagonize levodopa effects. It may also increase bleeding risk with anticoagulants (e.g., heparin, warfarin) or antiplatelet agents (e.g., aspirin, clopidogrel).

👥 Use in Specific Populations 46 words ▾

USE IN SPECIFIC POPULATIONS: The formula’s safety and efficacy have not been established in certain populations. Safety and effectiveness in pregnant or nursing women, pediatric patients, and geriatric patients have not been established. Use in these populations should be under the supervision of a healthcare provider.

🆘 Overdosage 146 words ▾

OVERDOSE: Signs and symptoms: Iron is toxic in excessive amounts. Acute ingestion of iron may cause nausea, vomiting, abdominal pain, and in severe cases, gastrointestinal bleeding, shock, cardiovascular collapse, and death. Other symptoms may include pallor, cyanosis, melena (black tarry stools), drowsiness, and coma.

Severe reactions, including fatalities, have occurred in children from accidental overdose. The estimated toxic dose of orally ingested elemental iron is approximately 300 mg/kg body weight. Treatment: For management of iron overdosage, initiate appropriate supportive and symptomatic therapy.

Gastric lavage may be performed using sodium bicarbonate solution or milk. Intravenous fluids and electrolyte replacement should be administered as indicated. Oxygen therapy may be required.

In cases of severe toxicity, chelation therapy with appropriate agents (e.g., deferoxamine) should be considered. Exchange transfusion may be indicated in life-threatening situations. Management should be guided by a healthcare provider based on clinical status and laboratory parameters.

🧬 Clinical Pharmacology 30 words ▾

CLINICAL PHARMACOLOGY: Vitamins and minerals are absorbed and metabolized through normal biological pathways, contributing to various physiological functions. The botanical extracts provide additional support for energy levels and overall well-being.

📦 How Supplied / Storage and Handling 52 words ▾

HOW SUPPLIED: Boostervite™ tablets are yellow to brown, speckled, film-coated tablets, supplied in bottles of 30 tablets (NDC 59088-022-54). Dispense in a tight, light-resistant container as defined in the USP/NF, with a child-resistant closure. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from light and moisture.

📦 Storage and Handling 23 words ▾

Do not use if the seal under the bottle cap is broken. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.

📋 Description 145 words ▾

DESCRIPTION: Each Tablet Contains: Vitamin C (as ascorbic acid)……………….……………… 100 mg Vitamin D3 (as cholecalciferol)…………….……. 10 mcg (400 IU) Thiamin (as thiamine mononitrate)…………...……………. 10 mg Riboflavin ...................…………………………...…………..

10 mg Niacin (as niacinamide)…………………………....…………10 mg Vitamin B6 (as pyridoxine hydrochloride)………….……….10 mg Folate (as L-5-Methyltetrahydrofolate calcium salt)……….. 1700 mcg DFE (1000 mcg L-5-Methylfolate) Vitamin B12 (as methylcobalamin)………………….….... 100 mcg Biotin (as d-Biotin)……………………...……....................

300 mcg Pantothenic Acid (as d-Calcium Pantothenate)………....… 50 mg Iron (as Ferrous Fumarate)……………………………......... 18 mg Withania somnifera (Ashwagandha) Root Powder….....…. 60 mg Brassica oleracea acephala (Kale) Powder……….…...….

2.5mg Brassica oleracea italica (Broccoli) Sprout Powder..…...... 2.5 mg Citrus sinensis (Orange) Juice Powder……....................... 2.5 mg Prunus cerasus (Tart Cherry) Extract.................................

2.5mg Other Ingredients: Croscarmellose Sodium, Dicalcium Phosphate, Magnesium Stearate (vegetable source), Microcrystalline Cellulose, Silicon Dioxide, Stearic Acid (vegetable source), Coating (Hydroxypropyl Methylcellulose, Polyethylene Glycol 400, Organic Maltodextrin, Organic Sunflower Lecithin, Organic Sunflower Oil, Organic Guar Gum).

⚠️ Precautions ~1 min read ▾

PRECAUTIONS: Folate in doses above 0.1 mg daily may obscure pernicious anemia, in that hematologic remission can occur while neurological manifestations remain progressive. There is a potential danger in administering folate to patients with undiagnosed anemia, since folate may obscure the diagnosis of pernicious anemia by alleviating the hematologic manifestations of the disease while allowing the neurological complications to progress. This may result in severe nervous system damage before the correct diagnosis is made.

Adequate doses of vitamin B12 may prevent, halt, or improve the neurological changes caused by pernicious anemia. The patient’s medical conditions and consumption of other drugs, herbs, and/or supplements should be considered. Use with caution in patients receiving sedatives, antihypertensive agents, antidiabetic medications, thyroid hormone therapy, or immunosuppressive therapy, as ashwagandha may potentiate pharmacologic effects.

To be used only under the supervision of a healthcare provider. Drug Interactions: Boostervite™ is not recommended for use in patients receiving levodopa, as pyridoxine may antagonize the effects of levodopa. Pyridoxine may antagonize levodopa effects.

It may also increase bleeding risk with anticoagulants (e.g., heparin, warfarin) or antiplatelet agents (e.g., aspirin, clopidogrel). Adverse Reactions: Allergic sensitization and other hypersensitivity reactions have been reported with oral folate supplementation. Ferrous Fumarate: Gastrointestinal disturbances, including anorexia, nausea, diarrhea, and constipation, have been reported.

These effects are generally mild and may resolve with continued use. Administration of Boostervite™ with food may reduce the occurrence of gastrointestinal disturbances, although iron absorption may be decreased when taken with meals. Adverse reactions have been reported with specific vitamins and minerals but generally at levels substantially higher than those contained herein.

However, allergic and idiosyncratic reactions are possible at lower levels. Iron, even at the usual recommended levels, has been associated with gastrointestinal intolerance in some patients. Call your healthcare provider for medical advice about side effects.

You may report side effects to PureTek Corporation at 1-877-921-7873 . You may also report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.

📄 Package Label / Principal Display Panel 13 words ▾

Boostervite™ Manufactured in the USA by: PureTek Corporation Panorama City, CA 91402 label

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Boostervite (this brand).

Top reported reactions

Fatigue3,675
Nausea3,233
Diarrhoea2,812
Headache2,601
Dizziness2,296
Dyspnoea2,044
Pain1,921

Age at onset

Neonate4
Infant15
Child51
Adolescent38
Adult1,012
Elderly1,025

Reporter sex

49,467 reports
Male · 34%
Female · 66%
Unknown · 0%

Serious outcomes

Hospitalization11,681
Death2,304
Disabling2,010
Life-threatening1,166
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 4,373 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

About this NDC listing & data coverage

Finished prescription product Marketed without an FDA application

Listed without an FDA application

This product's marketing category indicates it is marketed without an approved FDA application (no NDA, ANDA, or BLA on file). Having an NDC does not by itself establish FDA approval — the NDC Directory is a listing system, not an approval decision. Approval-linked data such as Orange Book therapeutic-equivalence ratings therefore does not apply.

What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos — Not published for this NDC No photo available yet for this listing.
Inactive ingredients (structured) — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available.
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Is this NDC FDA-approved?
An NDC listing does not by itself establish FDA approval — the NDC Directory records that a product is listed with FDA, not that it was reviewed and approved. This listing's marketing category is "Unapproved Drug Other". Products approved under an application carry an NDA, ANDA, or BLA number.
Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by PureTek Corporation. Listing status can change — the directory data on this page refreshes weekly.
Who lists this product with the FDA?
PureTek Corporation is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 59088-0020-54 · PureTek 59088-0078-54 · PureTek →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.